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A r t i c l e s marrow cells transduced with a retrovirus encoding BCR-ABL from 5-fluorouracil-treated Blk −/− donor mice developed CML significantly faster than did recipients of wild-type bone marrow cells transduced with BCR-ABL-encoding virus (Fig. 1c) . Accelerated disease phenotype correlated with a higher percentage and number of myeloid leukemia (GFP + Gr-1 + ) cells in peripheral blood (Fig. 1d,e) and more severe infiltration of leukemia cells in the spleen (Fig. 1f) . The lack of Blk did not affect the transduction efficiency of the retrovirus encoding BCR-ABL (Supplementary Fig. 2b ) or the homing of normal (Supplementary Fig. 2c ) and BCR-ABL-expressing ( Supplementary  Fig. 2d ) cells to the bone marrow after transplantation. Conversely, we overexpressed Blk in donor bone marrow cells by transducing the cells with a retrovirus encoding both BCR-ABL and Blk ( Supplementary  Fig. 3 ), which resulted in greater survival of CML mice (Fig. 1g) , correlating with a lower percentage of myeloid leukemia cells in peripheral blood (Fig. 1h) and lower infiltration of leukemia cells in the spleen and lung (Fig. 1i,j) . To determine whether Blk inhibits CML progression, we induced CML and then transduced bone marrow cells, which included established leukemia cells, with vector expressing human CD4 marker (MSCV-IRES-hCD4) or also expressing Blk (MSCV-Blk-IRES-hCD4). After sorting hCD4 + cells by magnetic-activated cell sorting (MACS), we normalized and transplanted an equal number of GFP + hCD4 + cells into recipient mice (Fig. 1k) . We observed that the percentage of GFP + hCD4 + leukemia cells in the two groups was initially similar (data not shown), but the percentage of Blk-expressing leukemia cells gradually decreased with time ( Fig. 1k) .
Suppression of LSCs in CML mice by Blk raised the possibility that restoration of Blk expression could synergize with BCR-ABL kinase inhibitor in CML treatment. We induced CML in mice through expression of BCR-ABL or BCR-ABL and Blk and treated these mice with a placebo or with imatinib. Either overexpression of Blk or imatinib treatment prolonged survival, as expected, but overexpression of Blk in npg combination with imatinib was much more effective, with approximately 40% of CML mice surviving longer than 130 d (Fig. 1l) . This therapeutic effect correlated with lower white blood cell counts (Fig. 1m ) and the disappearance of leukemia cells (Fig. 1n) , which was confirmed using real-time RT-PCR detection of BCR-ABL transcripts in cells from the peripheral blood of CML mice ( Supplementary Fig. 4) .
Blk suppresses the function of LSCs
The downregulation of Blk by BCR-ABL in LSCs and the ability of Blk to suppress CML development prompted us to test whether Blk suppresses LSCs. The percentages of total LSCs and long-term (CD34 − ) or short-term (CD34 + ) LSCs (LT-LSCs or ST-LSCs, respectively) in the bone marrow of recipients of BCR-ABL-expressing Blk −/− donor bone marrow cells were significantly higher than those in the bone marrow of recipients of BCR-ABL-expressing wild-type cells (Fig. 2a) (Fig. 2a) . To confirm the inhibitory effect of Blk on LSCs, we tested whether Blk overexpression caused a reduction in the percentage or number of LSCs in CML mice. We transduced bone marrow cells with viruses encoding BCR-ABL or BCR-ABL and Blk to induce CML and observed that the percentages and numbers of total LSCs, LT-LSCs and ST-LSCs were significantly lower in recipients of bone marrow cells expressing BCR-ABL and Blk than in recipients of cells expressing BCR-ABL alone (Fig. 2b) . To verify the ectopic expression of Blk, we sorted LSCs by fluorescence-activated cell sorting (FACS) and isolated total RNA for RT-RCR analysis; we found that Blk expression was largely but not completely restored to the endogenous level in LSCs (Fig. 2c) . To further examine the inhibitory effect of Blk on LSCs, we tested their ability to transfer disease to secondary recipient mice. Bone marrow cells were transduced with viruses encoding BCR-ABL or BCR-ABL and Blk to induce primary CML, and bone marrow cells from these CML mice were then transferred into secondary recipient mice. We found that Blk overexpression caused a significant delay in CML development in the secondary recipients (Fig. 2d) . 
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To more rigorously evaluate the inhibitory effect of Blk on LSC function, we examined whether Blk reduces the ability of LSCs to repopulate CML development. LSCs were sorted by FACS from the bone marrow of mice with primary CML induced by transplantation with CD45.2 donor bone marrow cells expressing BCR-ABL alone or with CD45.1 cells expressing BCR-ABL and Blk. Sorted CD45.2 and CD45.1 LSCs were mixed at a 1:1 ratio and were transplanted into recipient mice. At days 14, 23 and 28 after transplantation, fewer than 5% of GFP + Gr-1 + cells in the peripheral blood of the mice were CD45.1 leukemia cells that overexpressed Blk, whereas greater than 75-80% of GFP + Gr-1 + cells were CD45.2 leukemia cells that did not overexpress Blk (Fig. 2e) . Consistent with these results, at day 28 after transplantation, the percentage of CD45.1 + leukemia cells that overexpressed Blk in the bone marrow was also very low (Fig. 2e) . The suppression of LSCs by Blk can be explained, at least in part, by inhibition of cell cycle progression, as there were significantly fewer LSCs A r t i c l e s that overexpressed Blk in the S + G2/M phases of the cell cycle than LSCs that did not overexpress Blk (Fig. 2f) . In addition, we observed more apoptosis in LSCs from recipients of bone marrow cells transduced with viruses encoding both BCR-ABL and Blk (Fig. 2g) .
Blk does not suppress the function of normal HSCs
We asked whether Blk has a similar inhibitory effect on normal HSCs. Using real-time RT-PCR, we first assessed Blk expression in different hematopoietic stem and progenitor populations, including long-term HSCs (LT-HSCs; CD34 − Flt-3 − LSK), short-term HSCs (ST-HSCs; CD34 + Flt-3 − LSK), multipotential progenitors (MPPs; CD34 + Flt-3 + LSK), CMPs, MEPs and GMPs. We found that Blk was highly expressed in LT-HSCs but not in ST-HSCs, MPPs and progenitors, excluding MEPs with a higher level of Blk expression (Supplementary Fig. 5a ). Next, we examined the effect of Blk on normal hematopoiesis and HSCs. The percentages of total LSK cells, LT-HSCs, ST-HSCs, CMPs and MEPs were similar in the bone marrow of wild-type and Blk −/− mice, although the percentage of GMPs was higher in Blk −/− (0.19%) than in wild-type (0.12%) mice (Fig. 3a-c) . Notably, however, there was no significant difference in the percentage of more mature myeloid cells (Gr-1 + Mac-1 + ) in the bone marrow of wild-type and Blk −/− mice (Fig. 3d) . We also found that Blk deficiency did not affect cell cycle progression (Fig. 3e) or apoptosis ( Fig. 3f) of LSK cells.
To examine whether Blk affects the function of normal HSCs, we performed a competitive repopulation assay. We transplanted 2 × 10 5 bone marrow cells from wild-type or Blk −/− mice (CD45.2) into each lethally irradiated wild-type recipient (CD45.1) along with an equal number of wild-type competitor cells (CD45.1). The lineage contribution of wild-type or Blk −/− cells in recipient mice was evaluated 8, 12 and 16 weeks after transplantation. We observed similar percentages of donor-derived myeloid (Gr-1 + and Mac-1 + ) and T-lymphoid (CD4 + and CD8 + ) cells (Fig. 3g) , indicating that Blk did not affect the function of normal HSCs. Although Blk deficiency affected the percentage of B cells (B220 + ) (Fig. 3g) , this effect is likely due to the known role of Blk in B-cell development 17 . We also performed a colony-forming assay to examine the effect of Blk on progenitor cell function in vitro using sorted LSK cells from the bone marrow of wild-type and Blk −/− mice. Similar numbers and types of colonies were formed in the presence and absence of Blk (Fig. 3h) . Further, there was no significant difference in the ability of wild-type and Blk −/− bone marrow cells to rescue lethally irradiated mice (Fig. 3i) .
To provide additional evidence for the role of Blk in the regulation of HSC function, we tested whether overexpression of Blk suppresses HSCs. We transduced bone marrow cells from wild-type mice with retroviruses encoding GFP alone or Blk and GFP and then transplanted these cells into recipient mice (Fig. 3j) . Overexpression Fig. 5b ). (Fig. 3j) , and the percentage of GFP + LSK cells in the bone marrow of recipients of cells expressing GFP or Blk and GFP at 16 weeks was also similar (Fig. 3k) . In addition, there was no significant difference in cell cycle progression (Fig. 3l) Table 1 ).
Pax5 is an upstream regulator of Blk in LSCs
Pax5 binds to the Blk promoter and stimulates Blk expression 18 . We therefore considered the possibility that the downregulation of Blk expression by BCR-ABL in LSCs is mediated by Pax5. We found that BCR-ABL markedly downregulates Pax5 expression in LSCs (Fig. 4a) .
To test whether Pax5 suppresses LSCs and CML development, we generated a retroviral construct that coexpressed BCR-ABL and Pax5 (Fig. 4b) . We transduced bone marrow cells with viruses encoding BCR-ABL or BCR-ABL and Pax5 to induce CML. After 14 d, bone marrow cells from CML mice were analyzed for the percentages and numbers of LSCs. Pax5 overexpression caused marked lower numbers of total LSCs, LT-LSCs and ST-LSCs (Fig. 4c) . We next compared survival between the two transplantation groups. All recipients of BCR-ABL-expressing bone marrow cells died of CML within 3 weeks of transplantation, whereas fewer than 20% of the recipients of bone marrow cells expressing both BCR-ABL and Pax5 developed CML and died (Fig. 4d) , which correlated with the lower and gradually decreasing percentage of myeloid leukemia cells in peripheral blood during the course of the disease (Fig. 4e) and with less severe splenomegaly and leukemia cell infiltration in the spleen and lung (Fig. 4f) .
We also found that ectopically expressed Pax5 caused higher Blk expression in LSCs (Fig. 4g) , supporting the idea that Pax5 functions upstream of Blk to mediate the downregulation of Blk by BCR-ABL. To further test this idea, we transduced bone marrow cells from Blk −/− or wild-type mice with viruses expressing BCR-ABL alone or BCR-ABL and Pax5 to induce CML. Compared to recipients of Blk −/− bone marrow cells expressing BCR-ABL alone that had accelerated CML development (Fig. 4h) , recipients of Blk −/− bone marrow cells expressing both BCR-ABL and Pax5 died of CML much more slowly, although these mice developed CML significantly faster than recipients of wild-type bone marrow cells expressing BCR-ABL and Pax5. These results suggest that Blk is one but not the only downstream functional target gene of Pax5 in LSCs.
We tested whether Pax5 suppresses normal HSCs. We first assessed Pax5 expression in different hematopoietic stem and progenitor populations using quantitative RT-PCR (qRT-PCR) and found that Pax5 was highly expressed in LT-HSCs but not in ST-HSCs, MPPs and progenitors, excluding MEPs (Supplementary Fig. 6a ). Next, we transduced bone marrow cells from normal B6 mice with retroviruses encoding GFP alone or Pax5 and GFP, and the transduced cells were cultured under stem cell conditions for 4 d; FACS analyses of control or Pax5-expressing GFP + LSK cells were then performed. Pax5 overexpression was confirmed by RT-PCR (Supplementary Fig. 6b ). Pax5 reduced the percentage of LSK cells from 45.5% to 29.4% ( Supplementary  Fig. 6c ), suggesting that, unlike Blk, Pax5 has some effect on normal HSCs. This result further suggests that Pax5 also regulates other downstream genes besides Blk. However, when we monitored the distribution of different lineages 8, 12 and 16 weeks after transplantation, Fig. 6d) , suggesting that the function of HSCs was not significantly affected. Development of lymphoid (GFP + B220 + or GFP + CD3e + ) cells was affected by Pax5 (Supplementary Fig. 6d ), presumably due to the specific role of Pax5 in lymphoid development 19 (for further discussion, see the Supplementary Note).
c-Myc and Ebf1 mediate downregulation of Pax5 by BCR-ABL
We studied how BCR-ABL downregulates Pax5 expression. BCR-ABL induces c-Myc expression [20] [21] [22] , and analysis of the Pax5 promoter region identified a consensus c-Myc-binding motif 312 bp upstream of the transcription start site (Supplementary Fig. 7a ).
Chromatin immunoprecipitation (ChIP) analysis showed that c-Myc directly binds to this region but not to a region further upstream (Fig. 5a) . Therefore, we investigated whether BCR-ABL downregulates Pax5 through c-Myc using a luciferase assay. We found that expression of c-Myc caused a reduction in Pax5 promoter activity in a dose-dependent manner in NIH3T3 cells (Fig. 5b) . By mutating the c-Myc-binding site in the Pax5 promoter, we markedly rescued the suppression of luciferase activity by c-Myc (Fig. 5c) . These results indicate that c-Myc directly binds to the Pax5 promoter to suppress Pax5 expression. To determine whether c-Myc downregulates Pax5 expression in HSCs, we transduced bone marrow cells with a retrovirus expressing c-Myc ( Supplementary  Fig. 7b ) or, as a control, Pax5. qRT-PCR analysis showed that c-Myc significantly inhibited expression of Pax5 and Blk in LSK cells (Fig. 5d,e) , whereas Pax5 markedly enhanced Blk expression in these cells (Fig. 5e) .
The transcription factor Ebf1 binds to the Pax5 promoter and stimulates Pax5 expression 23, 24 , and our microarray results indicated that Ebf1 expression was significantly downregulated in LSCs (Supplementary Fig. 8 ). ChIP analysis showed that Ebf1 directly binds to the Pax5 promoter within the region from 1,638 to 1,647 bp upstream of the transcription start site (Fig. 5f) , consistent with previous results 23, 24 . Also, expression of Ebf1 caused higher Pax5 luciferase activity (Fig. 5g) . Although interferon regulatory factor 8 (Irf8) regulates the expression of Ebf1 and Pax5 (ref. 25, 26) , Irf8 had no effect on Pax5 promoter activity (Fig. 5g) . We mutated the Ebf1-binding site in the Pax5 promoter and found that the increase in luciferase activity mediated by Ebf1 was markedly inhibited (Fig. 5h) . It remained possible that c-Myc also downregulates Ebf1 expression, resulting in decreased Pax5 expression. Indeed, qRT-PCR analysis showed that BCR-ABL downregulated Ebf1 expression in LSCs (Fig. 5i) , and c-Myc downregulated Ebf1 expression in LSK cells (Fig. 5j) .
p27 functions downstream of Blk to suppress LSC proliferation
We attempted to identify genes required for Blk to suppress LSC proliferation and CML development. The mammalian cyclin-dependent kinase inhibitor 1b (Cdkn1b) p27 is a negative cell cycle regulator that blocks the G1-to-S phase transition 27 . BCR-ABL downregulates Cdkn1b expression through multiple mechanisms [28] [29] [30] [31] [32] . We compared the amount of p27 in 293T cells transfected with constructs expressing BCR-ABL alone or BCR-ABL and Blk and found that BCR-ABL downregulated p27 and that Blk restored p27 expression by inhibiting the expression of S-phase kinase-associated protein 2 (Skp2) (Fig. 6a) . The inhibition of Skp2 by Blk was confirmed by qRT-PCR (Supplementary Fig. 9a ). BCR-ABL and Blk did not alter the amounts of other cell cycle regulators, such as p21 and cyclin-dependent kinase 2 (Cdk2) (Fig. 6a) . To confirm that BCR-ABL functions through Blk to reduce p27 expression, we transduced wild-type or Blk −/− bone marrow cells with retrovirus expressing BCR-ABL and found that p27 expression was significantly lower in the absence of Blk (Fig. 6b  and Supplementary Fig. 9b) . Conversely, we overexpressed Blk in LSCs, both to verify that Blk increases p27 expression and to identify other Blk target genes. Bone marrow cells were transduced with retroviruses expressing GFP alone, BCR-ABL and GFP or BCR-ABL, Blk and GFP, and, 14 d after transplantation, bone marrow cells were isolated, and LSCs were sorted by FACS for isolation of total RNA for DNA microarray analysis. BCR-ABL downregulated the expression of Cdkn1b (encoding p27), which was reversed by Blk overexpression (Fig. 6c) . We also identified other genes that were significantly up-or downregulated by Blk in LSCs (Supplementary Table 2) .
To test whether p27 suppresses LSC proliferation and CML development, we transduced wild-type or Cdkn1b −/− bone marrow cells with (Fig. 6d) . Notably, only 20% of recipients of wild-type bone marrow cells expressing BCR-ABL died by 60 d after transplantation, whereas 90% of recipients of Cdkn1b −/− bone marrow cells expressing BCR-ABL died by 45 d (Fig. 6e) , correlating with a higher percentage and number of myeloid leukemia cells in the peripheral blood (Fig. 6f,g ). The regulation of p27 by Blk in cell cycle progression was further shown in cultured bone marrow cells from CML mice. Consistent with the results in 293T cells, Blk overexpression increased the expression of p27 but not of Cdk2 and Cyclin E (Supplementary Fig. 9c ). Collectively, these results indicate that p27 functions downstream of Blk to suppress LSC proliferation and CML development. By contrast, although Cdkn1b was induced to a high level by Blk in LSK cells (Supplementary Fig. 9d ), the percentages of LSKs were still similar in the bone marrow of mice receiving control and Blk-expressing bone marrow cells (Fig. 3k) , indicating that p27 did not suppress the proliferation of normal HSCs.
Suppression of CML does not require Blk kinase activity
To determine whether Blk kinase activity is required for suppression of CML, we analyzed three Blk mutants that had deletion of the entire kinase domain (∆Tk), a p.Lys263Glu alteration (K263E) or a p.Tyr383Phe alteration (Y383F) (Fig. 7a) . The K263E alteration causes a loss of Blk kinase activity, and the Y383F alteration reduces Blk autophosphorylation 33 . We coexpressed these three Blk mutants with BCR-ABL in 293T cells (Fig. 7b,c) and found that the kinase activity of Blk-K263E was almost completely absent and that autophosphorylation of Blk-Y383F was significantly lower than for wildtype Blk (Fig. 7b) . We transduced bone marrow cells with viruses expressing BCR-ABL alone or expressing BCR-ABL with wild-type Blk, Blk∆Tk, Blk-K263E or Blk-Y383F, which had similar viral titers (Supplementary Fig. 10 ). We found that recipients of bone marrow cells expressing BCR-ABL and Blk∆Tk or BCR-ABL alone developed CML similarly, as shown by survival (Fig. 7d) and infiltration of leukemia cells into the lung and spleen (Fig. 7e) . Unexpectedly, in recipients of bone marrow cells expressing BCR-ABL and Blk-K263E or BCR-ABL and Blk-Y383F, CML development was also suppressed (Fig. 7d) , correlating with decreased infiltration of leukemic cells into the spleen and lung (Fig. 7e) . Thus, suppression of CML development by Blk requires its kinase domain but not its kinase activity, although we cannot rule out the possibility that the very low levels of kinase activity of the Blk mutants are sufficient for CML suppression. It is possible that the ability of Blk to stimulate p27 expression involves Skp2 because p27 levels are inversely correlated with Skp2 expression 34 . Also, BCR-ABL stimulates cell cycle progression by promoting Skp2-mediated degradation of p27 (ref. 28) , and Skp2 is required for BCR-ABL-induced myeloproliferative disease 35 . We also found that Blk prevented BCR-ABL-induced Skp2 expression, which was dependent on the Blk kinase domain (Fig. 7f) .
BLK functions as a tumor suppressor in human CML cells
We first asked whether BLK expression was lost in human CML cells. We found that BLK expression was substantially lower in bone marrow cells from humans with CML compared to in normal human bone marrow cells (Fig. 8a) . We also analyzed a publicly available gene expression profiling database derived from analysis of human bulk CD34 + cells in individuals with CML 36 and found that BLK expression was markedly lower in the majority of persons with CML in the chronic, accelerated and blast crisis phases (Fig. 8b) . BCR-ABL significantly lowered BLK expression in human cord blood CD34 + cells transduced with virus expressing BCR-ABL, and this effect was not reversed by imatinib (Fig. 8c) , indicating that downregulation of BLK expression by BCR-ABL in human CML cells does not require BCR-ABL kinase activity. To examine whether the BCR-ABL kinase activityindependent regulation of BLK is at the level of CML stem cells, we first analyzed another publicly available DNA microarray study of human CML CD34 + CD38 − cells 37 and found that BLK expression was not altered by imatinib treatment (Fig. 8d) . We further analyzed BLK expression in quiescent and dividing CD34 + cells from individuals with CML on the basis of the results in a public database 38 . We found that the levels of BLK expression in quiescent and dividing CD34 + human CML stem cells were significantly lower than those in quiescent and dividing normal CD34 + cells (Fig. 8e ). In addition, the level of BLK expression in quiescent CML stem cells was significantly lower than that in dividing CML stem cells, but there was no difference in BLK expression between quiescent and dividing normal CD34 + cells (Fig. 8e) . Further, we sorted CD34 + CD38 − human CML stem cells 
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A r t i c l e s stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) by FACS into quiescent and dividing populations and isolated RNA for qRT-PCR analysis, confirming that BLK expression levels were lower in quiescent human CML stem cells than in dividing human CML stem cells (data not shown).
Next, we analyzed the functional effect of BLK on human CML stem cells. To infect quiescent cells, we used a lentiviral vector to express BLK in human CML cells. We purified lineage-negative cells from humans with primary CML, transduced the cells with virus encoding BLK (Fig. 8f) and subsequently labeled these transduced cells with CFSE to track quiescent and dividing CML stem cells 39 . We found that BLK overexpression inhibited the proliferation of CD34 + CD38 − CML stem cells, as shown by a lower percentage of CFSE lo cells in BLK-expressing CML stem cells relative to CML stem cells that were transduced with vector alone (Fig. 8g) . Also, BLK overexpression induced apoptosis of CD34 + CD38 − CML stem cells (Supplementary Fig. 11 ). Further, we performed a colonyforming assay to assess progenitor function 40 and found that BLK overexpression inhibited the colony-forming ability of human CML cells but not normal bone marrow cells (Fig. 8h) . BLK expression also inhibited the colony-forming ability of BCR-ABL-expressing human cord blood CD34 + cells (Fig. 8i) . Finally, we transduced BCR-ABL + human K562 cells with a retrovirus encoding GFP alone or BLK and GFP and showed that Blk-expressing K562 cells grew significantly slower than cells that did not express BLK (Fig. 8j) .
DISCUSSION
We show that Blk functions as a tumor suppressor in CML (pathway summarized in Fig. 8k) . Blk and BLK are downregulated by BCR-ABL in mouse and human CML hematopoietic cells, respectively. Of particular note, BLK expression is markedly downregulated in bulk CD34 + cells from the majority of humans with CML in the chronic, accelerated and blastic phases. Thus, suppression of BLK expression begins at an early stage of CML and is maintained throughout the course of disease.
Although BCR-ABL kinase inhibitors induce a complete cytogenetic response in the majority of humans with CML in the chronic phase of CML, they are incapable of eradicating LSCs 6, 13, 41 . We show that Blk suppresses LSCs without affecting normal HSCs or hematopoiesis. Thus, the BLK pathway provides a selective target for eradicating LSCs. CML could be treated by restoring BLK expression or upregulating the expression of other BLK pathway genes, such as PAX5 and CDKN1B. We note, however, that restoration of BLK expression in patients with CML would be technically challenging and might require, for example, gene therapy approaches.
The strategy of selectively targeting LSCs contrasts sharply with other therapeutic approaches that inhibit the function of gene products essential for both LSCs and normal HSCs [42] [43] [44] [45] [46] . For example, the Wnt signaling pathway is critical in regulating hematopoietic stem and progenitor cell function 43, 44 , and deletion of the Ctnnb1 gene causes a profound defect in LSCs and subsequent induction of CML by BCR-ABL 45, 47 . Inhibition of the Hedgehog pathway impairs both LSCs and normal HSCs 42, 46 .
The finding that Blk functions as a tumor suppressor is somewhat unexpected because some Src family kinases promote leukemogenesis [48] [49] [50] [51] . Paradoxically, Blk promotes normal B-cell development by cooperating with other Src family members. Pax5, which we show functions upstream of Blk, is also required for normal B-cell npg development 19, 52 . Deletions and mutations of PAX5 have been identified in human acute lymphoid leukemia 53, 54 , suggesting a tumor suppressor function. We show that Pax5 mediates downregulation of Blk by BCR-ABL through c-Myc and that p27 mediates the inhibitory effect of Blk on LSCs, although it is likely that there are other downstream Blk target genes. Mechanistically, Blk upregulates p27 through downregulation of Skp2. We have previously shown that LSCs in CML are also positively regulated by the Alox5 gene, which is upregulated by BCR-ABL 5 . Our data suggest that Blk regulates Alox5 in LSCs (H. Zhang, C. Peng, Y. Hu, Y. Chen and S. Li, unpublished data), and, accordingly, we should further elucidate the functional relationship between Blk and Alox5 in LSCs.
We found that Blk and p27 do not suppress the proliferation of normal HSCs, consistent with a previous finding that p27 has no effect on the number and self-renewal ability of HSCs 55 . Blk is a tyrosine kinase but was unexpectedly found to have tumor suppressor function unrelated to its kinase activity. Thus, a Src kinase inhibitor, such as dasatinib, would not inhibit BLK tumor suppressor activity in CML treatment. Downregulation of Blk by BCR-ABL is not reversed following inhibition of BCR-ABL kinase activity, consistent with the inability of imatinib to kill LSCs. Notably, Blk inhibits the proliferation of human CML stem cells, providing a rationale for targeting LSCs by restoring the BLK pathway.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. DNA microarray results have been deposited at the Gene Expression Omnibus (GEO) under accession GSE36096.
